Last week, I had a Brief Blog flagging that LUCIRA had filed for a $115M IPO based in part on its EUA for an all-in-one 30-minute COVID molecular test - here. (I included a link to the 285-page S-1 SEC document).
A few days later, here is another one. TALIS Biomedical has also filed for an IPO [TBD insert valuation here].
- See subscription coverage at SF Business Journal here.
- See open access coverage at Genomeweb here.
- See their 275-page S-1 SEC IPO document here.
Per Genomeweb, the firm is among a group of six diagnostics companies together awarded $250M in 2020 related to the COVID pandemic.
|Talis Biomedical Platform and Cartridge for COVID|